Epigenomics of alzheimer's disease

Journal of Experimental and Clinical Medicine (Taiwan)

Volumn 6, Issue 3, 2014, Pages 75-82

  Cacabelos, Ramón ^a,b   Torrellas, Clara ^b   López Muñoz, Francisco ^a,c,d  

^a CAMILO JOSÉ CELA UNIVERSITY   (Spain)

^b Centro de Investigacion Biomedica EuroEspes   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

^d Department of Pharmacology University of Alcalá ^*  (Spain)

Author keywords

DNA methylation; Epigenetics; Histone modifications; Noncoding RNAs

Indexed keywords

BETA SECRETASE; MICRORNA; RNA;

ALZHEIMER DISEASE; APOE GENE; APP GENE; BACE GENE; CELL AGGREGATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; DNA METHYLATION; EPIGENETICS; GENE; GENE EXPRESSION; HISTONE MODIFICATION; HUMAN; NERVE DEGENERATION; PRIORITY JOURNAL; PS1 GENE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84901664843     PISSN: 18783317     EISSN: 18783325     Source Type: Journal    
DOI: 10.1016/j.jecm.2014.03.010     Document Type: Review

References (88)

1. Cacabelos R. Pharmacogenomics in Alzheimer's disease. Methods Mol Biol 2008, 448:213-357.
2. Cacabelos R., Fernández-Novoa L., Lombardi V., Kubota Y., Takeda M. Molecular genetics of Alzheimer's disease and aging. Methods Find Exp Clin Pharmacol 2005, 27:1-573.
3. Szulwach K.E., Jin P. Integrating DNA methylation dynamics into a framework for understanding epigenetic codes. Bioessays 2014, 36:107-117.
4. Qureshi I.A., Mehler M.F. Advances in epigenetics and epigenomics for neurodegenerative diseases. Curr Neurol Neurosci Rep 2011, 11:464-473.
5. Wang J., Yu J.T., Tan M.S., Jiang T., Tan L. Epigenetic mechanisms in Alzheimer's disease: implications for pathogenesis and therapy. Ageing Res Rev 2013, 12:1024-1041.
6. Hartley I., Elkhoury F.F., Heon Shin J., Xie B., Gu X., Gao Y., Zhou D., et al. Long-lasting changes in DNA methylation following short-term hypoxic exposure in primary hippocampal neuronal cultures. PLoS One 2013, 8:e77859.
7. White A.O., Wood M.A. Does stress remove the HDAC brakes for the formation and persistence of long-term memory?. Neurobiol Learn Mem 2013, 10.1016/j.nlm.2013.10.007.
8. Gräff J., Tsai L.H. The potential of HDAC inhibitors as cognitive enhancers. Annu Rev Pharmacol Toxicol 2013, 53:311-330.
9. Brochier C., Langley B. Chromatin modifications associated with DNA double-strand breaks repair as potential targets for neurological diseases. Neurotherapeutics 2013, 10:817-830.
10. Coppedè F., Migliore L. Evidence linking genetics, environment, and epigenetics to impaired DNA repair in Alzheimer's disease. JAlzheimers Dis 2010, 20:953-966.
11. Zawia N.H., Lahiri D.K., Cardozo-Pelaez F. Epigenetics, oxidative stress, and Alzheimer disease. Free Radic Biol Med 2009, 46:1241-1249.
12. Mastroeni D., Grover A., Delvaux E., Whiteside C., Coleman P., Rogers J. Epigenetic mechanisms in Alzheimer's disease. Neurobiol Aging 2011, 32:1161-1180.
13. Hernández H.G., Mahecha M.F., Mejía A., Arboleda H., Forero D.A. Global long interspersed nuclear element 1 DNA methylation in a Colombian sample of patients with late-onset Alzheimer's disease. Am J Alzheimers Dis Other Demen 2014, 10.1177/1533317513505132.
14. Bollati V., Galimberti D., Pergoli L., Dalla Valle E., Barretta F., Cortini F., Scarpini E., et al. DNA methylation in repetitive elements and Alzheimer disease. Brain Behav Immun 2011, 25:1078-1083.
15. Tohgi H., Utsugisawa K., Nagane Y., Yoshimura M., Genda Y., Ukitsu M. Reduction with age in methylcytosine in the promoter region -224 approximately -101 of the amyloid precursor protein gene in autopsy human cortex. Brain Res Mol Brain Res 1999, 70:288-292.
16. Octave J.N., Pierrot N., Ferao Santos S., Nalivaeva N.N., Turner A.J. From synaptic spines to nuclear signaling: nuclear and synaptic actions of the amyloid precursor protein. JNeurochem 2013, 126:183-190.
17. Raina A., Kaul D. LXR-α genomics programmes neuronal death observed in Alzheimer's disease. Apoptosis 2010, 15:1461-1469.
18. Coppedè F. One-carbon metabolism and Alzheimer's disease: focus on epigenetics. Curr Genomics 2010, 11:246-260.
19. Wang S.C., Oelze B., Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS One 2008, 3:e2698.
20. Caesar I., Gandy S. Evidence that an APOE 4 'double whammy' increases risk for Alzheimer's disease. BMC Med 2012, 10:36.
21. Rauhala H.E., Porkka K.P., Saramäki O.R., Tammela T.L., Visakorpi T. Clusterin is epigenetically regulated in prostate cancer. Int J Cancer 2008, 123:1601-1609.
22. Tohgi H., Utsugisawa K., Nagane Y., Yoshimura M., Ukitsu M., Genda Y. The methylation status of cytosines in a gene promoter region alters with age to downregulate transcriptional activity in human cerebral cortex. Neurosci Lett 1999, 275:89-92.
23. Sontag E., Nunbhakdi-Craig V., Sontag J.M., Diaz-Arrastia R., Ogris E., Dayal S., Lentz S.R., et al. Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. JNeurosci 2007, 2007(27):2751-2759.
24. Zhou X.W., Gustafsson J.Å., Tanila H., Bjorkdahl C., Liu R., Winblad B., Pei J.J. Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. Neurobiol Dis 2008, 31:386-394.
25. Sanchez-Mut J.V., Aso E., Panayotis N., Lott I., Dierssen M., Rabano A., Urdinguio R.G., et al. DNA methylation map of mouse and human brain identifies target genes in Alzheimer's disease. Brain 2013, 136:3018-3027.
26. Silva P.N., Furuya T.K., Braga I.L., Rasmussen L.T., Labio R.W., Bertolucci P.H., Chen E.S., et al. Analysis of HSPA8 and HSPA9 mRNA expression and promoter methylation in the brain and blood of Alzheimer's disease patients. JAlzheimers Dis 2014, 38:165-170.
27. Chouliaras L., Rutten B.P., Kenis G., Peerbooms O., Visser P.J., Verhey F., van Os J., et al. Epigenetic regulation in the pathophysiology of Alzheimer's disease. Prog Neurobiol 2010, 90:498-510.
28. Chouliaras L., Mastroeni D., Delvaux E., Grover A., Kenis G., Hof P.R., Steinbusch H.W., et al. Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients. Neurobiol Aging 2013, 34:2091-2099.
29. Adwan L., Zawia N.H. Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease. Pharmacol Ther 2013, 139:41-50.
30. Zhang K., Schrag M., Crofton A., Trivedi R., Vinters H., Kirsch W. Targeted proteomics for quantification of histone acetylation in Alzheimer's disease. Proteomics 2012, 12:1261-1268.
31. Ding H., Dolan P.J., Johnson G.V.W. Histone deacetylase 6 interacts with the microtubule-associated protein tau. Neurochemistry 2008, 106:2119-2130.
32. Govindarajan N., Rao P., Burkhardt S., Sananbenesi F., Schlüter O.M., Bradke F., Lu J., et al. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. EMBO Mol Med 2013, 5:52-63.
33. Julien C., Tremblay C., Émond V. SIRT1 decrease parallels the accumulation of tau in Alzheimer disease. JNeuropathol Exp Neurol 2009, 68:48-58.
34. Donmez G., Wang D., Cohen D.E., Guarente L. SIRT1 suppresses-amyloid production by activating the α-secretase gene ADAM10. Cell 2010, 142:320-332.
35. Ryu H., Barrup M., Kowall N.W., McKee A.C. P3-260: Epigenetic modification in a monozygotic twin with Alzheimer's disease. Alzheimers Dement 2008, 4:T598.
36. Ogawa O., Zhu X., Lee H.G., Raina A., Obrenovich M.E., Bowser R., Ghanbari H.A., et al. Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: a mitotic catastrophe?. Acta Neuropathol 2003, 105:524-528.
37. Myung N.H., Zhu X., Kruman Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes. Age (Dordr) 2008, 30:209-215.
38. Francis Y.I., Fà M., Ashraf H., Zhang H., Staniszewski A., Latchman D.S., Arancio O. Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. JAlzheimers Dis 2009, 18:131-139.
39. Walker M.P., LaFerla F.M., Oddo S.S., Brewer G.J. Reversible epigenetic histone modifications and Bdnf expression in neurons with aging and from a mouse model of Alzheimer's disease. Age (Dordr) 2013, 35:519-531.
40. Liu R., Lei J.X., Luo C., Lan X., Chi L., Deng P., Lei S., et al. Increased EID1 nuclear translocation impairs synaptic plasticity and memory function associated with pathogenesis of Alzheimer's disease. Neurobiol Dis 2012, 45:902-912.
41. Koshibu K., Gräff J., Beullens M., Heitz F.D., Berchtold D., Russig H., Farinelli M., et al. Protein phosphatase 1 regulates the histone code for long-term memory. JNeurosci 2009, 29:13079-13089.
42. Peleg S., Sananbenesi F., Zovoilis A., Burkhardt S., Bahari-Javan S., Agis-Balboa R.C., Cota P., et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 2010, 328:753-756.
43. Fischer A., Sananbenesi F., Wang X., Dobbin M., Tsai L.H. Recovery of learning and memory is associated with chromatin remodelling. Nature 2007, 447:178-182.
44. Gräff J., Rei D., Guan J.S., Wang W.Y., Seo J., Hennig K.M., Nieland T.J., et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012, 483:222-226.
45. Kim M.S., Akhtar M.W., Adachi M., Mahgoub M., Bassel-Duby R., Kavalali E.T., Olson E.N., et al. An essential role for histone deacetylase 4 in synaptic plasticity and memory formation. JNeurosci 2012, 32:10879-10886.
46. Tian F., Marini A.M., Lipsky R.H. Effects of histone deacetylase inhibitor Trichostatin A on epigenetic changes and transcriptional activation of Bdnf promoter 1 by rat hippocampal neurons. Ann N Y Acad Sci 2010, 1199:186-193.
47. Gupta S., Kim S.Y., Artis S., Molfese D.L., Schumacher A., Sweatt J.D., Paylor R.E., et al. Histone methylation regulates memory formation. JNeurosci 2010, 30:3589-3599.
48. Lithner C.U., Hernandez C.M., Nordberg A., Sweatt J.D. Epigenetic changes related to beta-amyloid-implications for Alzheimer's disease. Alzheimers Dement 2009, 5:P304.
49. Vogel-Ciernia A., Wood M.A. Neuron-specific chromatin remodeling: a missing link in epigenetic mechanisms underlying synaptic plasticity, memory, and intellectual disability disorders. Neuropharmacology 2014, 10.1016/j.neuropharm.2013.10.002.
50. Zhang L., Zhang Y., Chou C.J., Inks E.S., Wang X., Li X., Hou J., Xu W. Histone deacetylase inhibitors with enhanced enzymatic inhibition effects and potent invitro and invivo antitumor activities. Chem Med Chem 2014, 9:638-648.
51. Pirooznia S.K., Elefant F. AHAT for sleep?: epigenetic regulation of sleep by Tip60 in Drosophila. Fly (Austin) 2013, 7:99-104.
52. Aljada A., Dong L., Mousa S.A. Sirtuin-targeting drugs: mechanisms of action and potential therapeutic applications. Curr Opin Investig Drugs 2010, 11:1158-1168.
53. Wu P., Zuo X., Deng H., Liu X., Liu L., Ji A. Roles of long noncoding RNAs in brain development, functional diversification and neurodegenerative diseases. Brain Res Bull 2013, 97:69-80.
54. Van den Hove D.L., Kompotis K., Lardenoije R., Kenis G., Mill J., Steinbusch H.W., Lesch K.P., et al. Epigenetically regulated microRNAs in Alzheimer's disease. Neurobiol Aging 2014, 35:731-745.
55. Kumar P., Dezso Z., Mackenzie C., Oestreicher J., Agoulnik S., Byrne M., Bernier F., et al. Circulating miRNA biomarkers for Alzheimer's disease. PLoS One 2013, 8:e69807.
56. Leidinger P., Backes C., Deutscher S., Schmitt K., Mueller S.C., Frese K., Haas J., et al. Ablood based 12-miRNA signature of Alzheimer disease patients. Genome Biol 2013, 14:R78.
57. Alexandrov P.N., Dua P., Hill J.M., Bhattacharjee S., Zhao Y., Lukiw W.J. microRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int J Biochem Mol Biol 2012, 3:365-373.
58. Long J.M., Lahiri D.K. MicroRNA-101 downregulates Alzheimer's amyloid-precursor protein levels in human cell cultures and is differentially expressed. Biochem Biophys Res Commun 2011, 404:889-895.
59. Liu W., Liu C., Zhu J., Shu P., Yin B., Gong Y., Qiang B., et al. MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice. Neurobiol Aging 2012, 33:522-534.
60. Smith P., Al Hashimi A., Girard J., Delay C., Hébert S.S. Invivo regulation of amyloid precursor protein neuronal splicing by microRNAs. JNeurochem 2011, 116:240-247.
61. Fang M., Wang J., Zhang X. The miR-124 regulates the expression of BACE1/β-secretase correlated with cell death in Alzheimer's disease. Toxicol Lett 2012, 209:94-105.
62. Hébert S.S., Horré K., Nicolaï L., Papadopoulou A.S., Mandemakers W., Silahtaroglu A.N., Kauppinen S., et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/-secretase expression. Proc Natl Acad Sci U S A 2008, 105:6415-6420.
63. Zong Y., Wang H., Dong W., Quan X., Zhu H., Xu Y., Huang L., et al. miR-29c regulates BACE1 protein expression. Brain Res 2011, 1395:108-115.
64. Wang W.X., Rajeev B.W., Stromberg A.J., Ren N., Tang G., Huang Q., Rigoutsos I., et al. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of β-site amyloid precursor protein-cleaving enzyme 1. JNeurosci 2008, 28:1213-1223.
65. Zhu H.C., Wang L.M., Wang M., Song B., Tan S., Teng J.F., Duan D.X. MicroRNA-195 downregulates Alzheimer's disease amyloid-β production by targeting BACE1. Brain Res Bull 2012, 88:596-601.
66. Faghihi M.A., Modarresi F., Khalil A.M., Wood D.E., Sahagan B.G., Morgan T.E., Finch C.E., et al. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med 2008, 14:723-730.
67. Faghihi M.A., Zhang M., Huang J., Modarresi F., Van der Brug M.P., Nalls M.A., Cookson M.R., et al. Research evidence for natural antisense transcript-mediated inhibition of microRNA function. Genome Biol 2010, 11:R56.
68. Massone S., Ciarlo E., Vella S., Nizzari M., Florio T., Russo C., Cancedda R., et al. NDM29, A RNA polymerase III-dependent non coding RNA, promotes amyloidogenic processing of amyloid precursor protein (APP) and amyloid secretion. Biochim Biophys Acta 2012, 1823:1170-1177.
69. Wang W.X., Huang Q., Hu Y., Stromberg A.J., Nelson P.T. Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter. Acta Neuropathol 2011, 121:193-205.
70. Geekiyanage H., Chan C. MicroRNA-137/181c regulates serine palmitoyltransferase and in turn amyloid, novel targets in sporadic Alzheimer's disease. JNeurosci 2011, 31:14820-14830.
71. Akram A., Schmeidler J., Katsel P., Hof P.R., Haroutunian V. Increased expression of cholesterol transporter ABCA1 is highly correlated with severity of dementia in AD hippocampus. Brain Res 2010, 1318:167-177.
72. Massone S., Vassallo I., Fiorino G., Castelnuovo M., Barbieri F., Borghi R., Tabaton M., et al. 17A, a novel non-coding RNA, regulates GABA B alternative splicing and signaling in response to inflammatory stimuli and in Alzheimer disease. Neurobiol Dis 2011, 41:308-317.
73. Smith P.Y., Delay C., Girard J., Papon M.A., Planel E., Sergeant N., Buée L., et al. MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. Hum Mol Genet 2011, 20:4016-4024.
74. Hébert S.S., Papadopoulou A.S., Smith P., Galas M.C., Planel E., Silahtaroglu A.N., Sergeant N., et al. Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum Mol Genet 2010, 19:3959-3969.
75. Caputo V., Sinibaldi L., Fiorentino A., Parisi C., Catalanotto C., Pasini A., Cogoni C., et al. Brain derived neurotrophic factor (BDNF) expression is regulated by microRNAs miR-26a and miR-26b allele-specific binding. PLoS One 2011, 6:e28656.
76. Liu H.C., Leu S.J., Chuang D.M. Roles of glycogen synthase kinase-3 in Alzheimer's disease: from pathology to treatment target. JExp Clin Med 2012, 4:135-139.
77. Cogswell J.P., Ward J., Taylor I.A., Waters M., Shi Y., Cannon B., Kelnar K., et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. JAlzheimers Dis 2008, 14:27-41.
78. Bilen J., Liu N., Burnett B.G., Pittman R.N., Bonini N.M. MicroRNA pathways modulate polyglutamine-induced neurodegeneration. Mol Cell 2006, 24:157-163.
79. Min S.W., Cho S.H., Zhou Y., Schroeder S., Haroutunian V., Seeley W.W., Huang E.J., et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010, 67:953-966.
80. Schonrock N., Humphreys D.T., Preiss T., Götz J. Target gene repression mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-β. JMol Neurosci 2012, 46:324-335.
81. Carrettiero D.C., Hernandez I., Neveu P., Papagiannakopoulos T., Kosik K.S. The cochaperone BAG2 sweeps paired helical filament-insoluble tau from the microtubule. JNeurosci 2009, 29:2151-2161.
82. Cui J.G., Li Y.Y., Zhao Y., Bhattacharjee S., Lukiw W.J. Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease. JBiol Chem 2010, 285:38951-38960.
83. Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-B-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006, 103:12481-12486.
84. Lukiw W.J., Zhao Y., Cui J.G. An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. JBiol Chem 2008, 283:31315-31322.
85. Li Y.Y., Cui J.G., Dua P., Pogue A.I., Bhattacharjee S., Lukiw W.J. Differential expression of miRNA-146a-regulated inflammatory genes in human primary neural, astroglial and microglial cells. Neurosci Lett 2011, 499:109-113.
86. Sethi P., Lukiw W.J. Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex. Neurosci Lett 2009, 459:100-104.
87. Popov N., Gil J. Epigenetic regulation of the INK4b-ARF-INK4a locus: in sickness and in health. Epigenetics 2010, 5:685-690.
88. Cacabelos R. World guide for drug use and pharmacogenomics 2012, Corunna: EuroEspes Publishing.